New eye injection aims to tackle Diabetes-Related vision loss
NCT ID NCT06701721
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests an experimental drug called THN391, given as an injection into the eye, for people with diabetic macular edema (DME) — a condition where fluid builds up in the retina due to diabetes, causing vision loss. The trial involves 21 adults aged 18 to 80 with DME and vision loss. Researchers will check for side effects and measure changes in vision and retinal swelling over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
THN391
What this could lead to
If successful, THN391 could offer a new treatment option for diabetic macular edema, potentially improving vision and reducing retinal swelling.
What could go wrong
This is an early-phase trial with only 21 participants, so results may not apply broadly. The drug may cause side effects or fail to improve vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartphone Screening for Eye Diseases - NCT03076697
- Biosimilar Ranibizumab for Diabetic Macular Edem NCT07663370
- Faricimab for Diabetic Macular Edema: ALTIMETER NCT04597918
- Home Monitoring for Diabetic Macular Edema - NCT06610747
- VIEW II: Community Eye Screening Trial (NCT03752840)
- Biomarker of Diabetic Retinopathy Study | NCT05079399
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye Surgery Associates Pty Ltd
RECRUITINGMalvern, Victoria, 3144, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Marsden Eye Specialists
RECRUITINGParramatta, New South Wales, 2150, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Princess Alexandria Hospital
RECRUITINGWoolloongabba, Queensland, 4102, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
South Eastern Sydney Local Health District
RECRUITINGSydney, New South Wales, 2000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sunshine Eye Surgeons
RECRUITINGAlbans, Victoria, 3021, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sydney West Retina
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••